NASDAQ · DWTX
Dogwood Therapeutics, Inc.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
Loading market information…
NASDAQ · BRTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BioRestorative Therapies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioRestorative Therapies, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$1.40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioRestorative Therapies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 4, 2025 | -$7.50-38.89% vs estimate | $500.00K+3.45% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$2.60+69.77% vs estimate | $234.00K-50.74% vs estimate |
|---|
| Q2 2024 | Aug 13, 2024 | -$10.00+10.71% vs estimate | $89.00K+790.0% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
$0.98-$0.01 (-1.01%)
Cocrystal Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.3% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$0.92+$0.02 (+2.48%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 56.69% below the high.
$0.83+$0.00 (+0.35%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.61% below the high.
